REG - Oxford Nanopore Tech - Chief Executive Officer Succession

Oxford Nanopore TechnologiesAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250811:nRSK7098Ua&default-theme=true

RNS Number : 7098U  Oxford Nanopore Technologies plc  11 August 2025

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

Oxford Nanopore Technologies plc

("Oxford Nanopore" or the "Company")

Chief Executive Officer Succession

11 August 2025

Oxford Nanopore Technologies plc (LSE: ONT), the company delivering a new
generation of molecular sensing technology based on nanopores, today
announces that Gordon Sanghera has notified the Board of his intention to step
down as Chief Executive Officer (CEO) and from the Board by the end of 2026,
after more than 20 years in the role.

As part of a long-standing succession planning process, the Board has now
commenced a formal search for a successor to lead the Company through its next
phase of growth and commercialisation.

Duncan Tatton-Brown, Chair of Oxford Nanopore, commented:

"Two decades ago, Gordon co-founded Oxford Nanopore with the bold ambition to
transform molecular analysis. He has since led the Company's growth into a
global business, built a highly differentiated technology platform and
fostered a culture of innovation and collaboration that underpins its success.
These foundations have supported sustained, above-market growth and position
Oxford Nanopore well for the future.

"On behalf of the Board, I want to thank Gordon for his visionary leadership
and unwavering commitment to Oxford Nanopore. We are well prepared from a
succession perspective and will continue to work closely with Gordon to
support a smooth transition as we look to appoint his successor. The Board is
focused on finding a leader with the vision and capabilities to further
advance our growth strategy, driving long term value creation for our
stakeholders."

Gordon Sanghera, CEO of Oxford Nanopore, commented:

"It has been a great honour to co-found and lead Oxford Nanopore. I've had the
privilege of working with an exceptional team whose talent and dedication have
underpinned the remarkable progress we've achieved together, shaping the
Company into the innovative force it is today.

"By next year I will have been CEO of Oxford Nanopore for 21 years. With
strong foundations in place for the Company's continued success, I believe
this will be the right time for me to pass the reins to a new leader. In
making this decision it has been important to me that the Board have ample
time to identify a successor to ensure a smooth transition.

"Until then, I remain resolutely focused on executing our strategic
priorities, continuing our strong performance, and driving the business to
profitability. With strong momentum across all our geographies and target end
markets -as demonstrated in our recent half-year update- I'm confident Oxford
Nanopore is well-positioned to capture the significant opportunity ahead and
continue delivering for our customers, partners, employees and shareholders."

Gordon co-founded Oxford Nanopore in 2005 and has served as CEO since its
inception, leading the development and commercialisation of its pioneering
nanopore-based sensing technology. Under his leadership, the Company set out
to transform molecular analysis by delivering richer biological data faster,
more affordably, and more accessibly than legacy technologies. This vision
began to materialise with the launch of the MinION in 2015, the world's first
portable sequencing device, and has since evolved into a broad portfolio of
devices serving customers in over 125 countries across both Research and
Applied markets. The impact of Oxford Nanopore's technology is reflected in
more than 14,000 peer-reviewed publications and sustained, above-market
growth. In recognition of his role in advancing technologies that have had
global scientific and medical impact, Gordon was appointed Commander of the
Most Excellent Order of the British Empire (CBE) in the 2023 New Year Honours.

 

-ENDS-

This announcement contains inside information for the purposes of the UK
version of the market abuse regulation (EU no. 596/2014), which forms part of
English law by virtue of the European Union (Withdrawal) Act 2018. The person
responsible for arranging the release of this announcement on behalf of the
Company is Hannah Coote, Company Secretary of Oxford Nanopore Technologies
plc.

 

 

For further information, please contact:

Oxford Nanopore Technologies plc

Investors:         ir@nanoporetech.com (mailto:ir@nanoporetech.com)

Media:              media@nanoporetech.com
(mailto:media@nanoporetech.com)

 

Teneo (communications adviser to the Company)

Tom Murray, Lisa Jarrett-Kerr, Jo Blackshaw

+44 (0) 20 7353 4200

OxfordNanoporeTechnologies@teneo.com
(mailto:OxfordNanoporeTechnologies@teneo.com)

 

About Oxford Nanopore Technologies plc:

Oxford Nanopore Technologies' goal is to bring the widest benefits to society
through enabling the analysis of anything, by anyone, anywhere. The Group has
developed a new generation of nanopore-based sensing technology that is
currently used for real-time, high-performance, accessible, and scalable
analysis of DNA and RNA. The technology is used in more than 125 countries,
to understand the biology of humans, plants, animals, bacteria, viruses and
environments as well as to understand diseases such as cancer.  Oxford
Nanopore's technology also has the potential to provide broad, high impact,
rapid insights in a number of areas including healthcare, food and
agriculture.

For more information please visit: www.nanoporetech.com
(http://www.nanoporetech.com/)

 

Forward-looking statements

This announcement contains certain forward-looking statements. For example,
statements regarding expected revenue growth and profit margins are
forward-looking statements. Phrases such as "aim", "plan", "expect", "intend",
"anticipate", "believe", "estimate", "target", and similar expressions of a
future or forward-looking nature should also be considered forward-looking
statements. Forward-looking statements address our expected future business
and financial performance and financial condition, and by definition address
matters that are, to different degrees, uncertain. Our results could be
affected by macroeconomic conditions, delays or challenges in manufacturing or
delivering of products to our customers, suspensions of large projects and/or
acceleration of large products or accelerated adoption of pathogen
surveillance or applied uses of our products. These or other uncertainties may
cause our actual future results to be materially different than those
expressed in our forward-looking statements.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAFLFLRTSIILIE